Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer - Wikidata - wikimedia - TriplyDB

Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer

Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer

http://www.wikidata.org/entity/Q28476850

about

Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication EGF receptor-targeted nanocarriers for enhanced cancer treatment Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells The 18-kDa translocator protein (TSPO) disrupts mammary epithelial morphogenesis and promotes breast cancer cell migration Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases Adjudin disrupts spermatogenesis via the action of some unlikely partners: Eps8, Arp2/3 complex, drebrin E, PAR6 and 14-3-3 Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer model.Therapeutic Efficacy of Orally Delivered Doxorubicin Nanoparticles in Rat Tongue Cancer Induced by 4-Nitroquinoline 1-Oxide.Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine.Utilisation of nanoparticle technology in cancer chemoresistance.Histone Deacetylase-3/CAGE Axis Targets EGFR Signaling and Regulates the Response to Anti-Cancer Drugs Interaction of oligomeric breast cancer resistant protein (BCRP) with adjudin: a male contraceptive with anti-cancer activity.Targeted polymeric therapeutic nanoparticles: design, development and clinical translation Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models Targeting the metabolic microenvironment of tumors.Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy.Tumor aerobic glycolysis: new insights into therapeutic strategies with targeted delivery.Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells.Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?Adjudin--A Male Contraceptive with Other Biological Activities.Targeting cancer cell mitochondria as a therapeutic approach: recent updates.The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer.Peptide GE11-Polyethylene Glycol-Polyethylenimine for targeted gene delivery in laryngeal cancer.Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.The clinical relevance and prognostic significance of adenosine triphosphate ATP-binding cassette (ABCB5) and multidrug resistance (MDR1) genes expression in acute leukemia: an Egyptian study.GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers Implications of therapy-induced selective autophagy on tumor metabolism and survival.The potential of multi-compound nanoparticles to bypass drug resistance in cancer.Fast-Clearable Nanocarriers Conducting Chemo/Photothermal Combination Therapy to Inhibit Recurrence of Malignant Tumors.GE11 Peptide as an Active Targeting Agent in Antitumor Therapy: A Minireview.Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer.

P2860

Q26795759-BCCFFE08-8B26-465E-905C-157B76744A97 Q27013001-F009A8E7-F922-4CBA-ACF1-B02722E5C644 Q28391849-7BE78E9E-EB46-4303-BBCA-D9DBD78EE017 Q28393898-6BC64766-4327-4D8E-BBA8-A77078E89DB6 Q28535344-112A2830-1205-4D10-8F92-E21E114DA8EB Q28548580-5C109D0D-9C30-4D15-8496-D73432598D05 Q28975477-FE469C7A-F656-462F-8825-01CBDD38A620 Q34214594-BCDC3352-137E-4B78-974F-6C668F14FACE Q34293616-09469B2A-B955-4376-959B-0B4841A37407 Q35895231-FD8006E1-2084-4118-8DA4-DB90C9EB82FE Q36157045-5E68C5D6-6C1E-4C5E-9987-0187B4930385 Q36419289-80754965-9529-4768-B1D5-5E02A387780D Q36421258-19DF85AE-8645-4540-BEC6-4335C860E7F3 Q36693836-ECA4BDB5-E12F-4B60-BE5B-08DC57A257E3 Q36767061-F546FEF0-EF46-4108-9C5D-DF21FE20E34A Q36934007-AC8995F1-4191-458B-AA50-C6C47B661AAF Q37013417-18F2C92E-52B1-4122-B86A-FE7288B451D0 Q37229190-FC3632EB-AB6C-4CE3-A190-CC0D2EA011EF Q37663392-936A4402-9BCD-4045-B848-4D5FB262D052 Q38132274-1754F06B-FB94-49EC-B5D9-472A72DC0A31 Q38206826-FC36D605-2E32-4F90-AFEF-6512BE579D75 Q38322466-034BE548-A02C-4F48-929B-BEFF7FABBE80 Q38606849-68395A7C-9557-4A0E-AF01-5EC29B8B0B1D Q38618636-E016D26F-56E5-4B75-9A79-FA02B26F1545 Q38668524-05A7A2C6-A446-4524-8A42-3EC35C5FC8EB Q38809044-8F1AB192-DE67-48F6-8C9B-BE1D6EE9954B Q38871170-72978BC2-0551-43AC-9BBA-BB79401C8258 Q38930537-A5DC93F0-4D08-4BD7-913B-539FA0FC4566 Q38999278-C9CE13A2-D046-4F06-9F2F-D2CE338D1D38 Q41385956-C82A60D5-B29C-4786-B7F6-793C04082897 Q42541156-7A562DF4-6FF8-45B3-8F2A-FEAF8BC074FF Q47114290-AE91A4F3-6D10-450B-B8E5-F7C9D0FFB1DC Q47830298-CC5DD78D-D80C-4829-AB6F-291F0FEF473F Q48356798-0707C824-D9B0-42E0-AC9C-B313C68C4305 Q54414564-857EBA90-0A62-4B22-8FE9-55F86D0F017A

P2860

Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer

http://www.wikidata.org/entity/Q28476850

description

2011 nî lūn-bûn

@nan

2011 թուականին հրատարակուած գիտական յօդուած

@hyw

2011 թվականին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Therapeutic efficacy and safet ...... of multi-drug resistant cancer

@ast

Therapeutic efficacy and safet ...... of multi-drug resistant cancer

@en

Therapeutic efficacy and safet ...... of multi-drug resistant cancer

@nl

type

label

Therapeutic efficacy and safet ...... of multi-drug resistant cancer

@ast

Therapeutic efficacy and safet ...... of multi-drug resistant cancer

@en

Therapeutic efficacy and safet ...... of multi-drug resistant cancer

@nl

prefLabel

Therapeutic efficacy and safet ...... of multi-drug resistant cancer

@ast

Therapeutic efficacy and safet ...... of multi-drug resistant cancer

@en

Therapeutic efficacy and safet ...... of multi-drug resistant cancer

@nl

P1433

Q28476850-24B89004-26C9-4DAB-A57C-C75626512FE0

P1476

Q28476850-A8AC63D2-D349-4F2C-8CFC-237A691065D7

P2093

Q28476850-02BF8E54-81EE-4A97-9974-21609F50A9CD

Q28476850-42264B63-AFB6-4799-9843-6EF4371D6E37

Q28476850-88CCCF01-D925-44FD-8CE4-9291E6061029

P2860

Q28476850-04E81E7B-7DFE-4963-A0A4-20FC0CA03085

Q28476850-1D281C2E-5BEF-4A71-B8E2-5EB073120F02

Q28476850-22B5F2AD-A202-4E5C-AF7F-CAA1336C7D85

Q28476850-364BF17F-1E31-4CDD-B803-977A93459740

Q28476850-36BBBE7A-1266-4C3A-BD9D-6E21B753721C

Q28476850-6680589B-5CF7-41AB-9F81-3B8C7D137128

Q28476850-7A72C2F2-1714-428C-8FB9-700B6A6484F4

Q28476850-7BF6105E-3A6D-4D1E-81DC-A1C41B172DD3

Q28476850-7C0E79B3-76DE-439A-8BBE-AE7B99941E29

Q28476850-7DCFE85E-238D-42C3-8B5A-E59BD9231AED

P304

Q28476850-D02BE2E4-F038-4503-B5F2-DB8C2FB54CAC

P31

Q28476850-6EDC2619-AF3E-4B22-B3CC-8DC6F1974ECD

P356

Q28476850-CD2CAD38-A075-435E-809D-E9CCE0B014DE

P407

Q28476850-AC362555-6D08-4AF5-BA92-5D9EC87BA8BC

P433

Q28476850-EFE4CD54-60EA-4E15-BE49-17D486641DA2

P478

Q28476850-179C363D-3677-4398-A2AA-0C7C29A2C327

P577

Q28476850-554425D6-C927-4D1A-960B-717077061CB6

P5875

Q28476850-4EBBE15F-6943-4925-9C0D-98987DBAD7A3

P698

Q28476850-E5C73E17-BD0D-4FC9-8C2C-BC93D1BD4948

P921

Q28476850-A6AB88D5-FCC0-4C72-8615-2E415999F499

Q28476850-DC762CDD-D7FE-4DD1-8171-4163D910E635

P932

Q28476850-14E51F6B-28E9-407E-8C63-2B674230C167

P356

JOURNAL.PONE.0024075

P1433

P1476

Therapeutic efficacy and safet ...... of multi-drug resistant cancer

@en

P2093

Lara Milane

http://www.w3.org/2001/XMLSchema#string

Mansoor Amiji

http://www.w3.org/2001/XMLSchema#string

Zhenfeng Duan

http://www.w3.org/2001/XMLSchema#string

P2860

Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria

Targeting HIF-1 for cancer therapy

Signal transduction to hypoxia-inducible factor 1

Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen

Why do cancers have high aerobic glycolysis?

Hypoxia--a key regulatory factor in tumour growth

Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics.

The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?

Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer.

Mechanisms of multidrug resistance in cancer treatment.

P304

e24075

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0024075

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51652939

http://www.w3.org/2001/XMLSchema#string

P698

21931642

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

P932

3169576

http://www.w3.org/2001/XMLSchema#string